XNW29016

About Evopoint Biosciences

Evopoint Biosciences is a rapidly emerging, privately held biopharmaceutical company with a robust pipeline of over 17 programs, including 7 in clinical stages. Its strategy is built on three proprietary technology platforms—Small Molecule, Novel Antibody, and Targeted Protein Degradation—targeting high-value areas in oncology and anti-infectives. The company has demonstrated significant validation through over $2 billion in landmark licensing deals with major pharmaceutical partners and has advanced multiple candidates to Phase III or NDA stages, supported by regulatory designations from the FDA and NMPA. Evopoint is actively building an integrated, end-to-end ecosystem from discovery to global commercialization.

Therapeutic Areas

Other Not Specified Drugs